Working… Menu

Effects of SRX246 on an Experimental Model of Fear and Anxiety in Humans

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02922166
Recruitment Status : Unknown
Verified June 2019 by Azevan Pharmaceuticals.
Recruitment status was:  Active, not recruiting
First Posted : October 4, 2016
Last Update Posted : June 10, 2019
National Institute of Mental Health (NIMH)
Information provided by (Responsible Party):
Azevan Pharmaceuticals

Brief Summary:
To determine the effects of SRX246 on fear and anxiety based on fear-potentiated startle in humans. Additionally, the effects of the compound on emotion recognition will be explored.

Condition or disease Intervention/treatment Phase
Fear Anxiety Drug: SRX246 Drug: Placebo Phase 1

Detailed Description:
The study will use a double-blind, cross-over design in which each subject will receive placebo and SRX246 for 5-7 days before testing (given in counter-balanced order). The study will examine the effect of the drug on the potentiation of startle using a well-established paradigm that involves anticipation of no-shock, predictable shock, and unpredictable shock. Drug effects on emotion recognition will also be explored.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 36 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Effects of SRX246, a Vasopressin Receptor (V1a) Antagonist, on an Experimental Model of Fear and Anxiety in Humans
Actual Study Start Date : February 3, 2017
Actual Primary Completion Date : May 10, 2019
Estimated Study Completion Date : December 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Anxiety

Arm Intervention/treatment
Experimental: SRX246
SRX246 oral dosage capsules, daily dose to be taken bid, for up to 7 days
Drug: SRX246
oral capsule

Placebo Comparator: Placebo
Placebo oral dosage capsules, daily dose to be taken bid, for up to 7 days
Drug: Placebo
oral capsule

Primary Outcome Measures :
  1. Change in startle reflex between SRX246 and Placebo [ Time Frame: up to 7 days ]
    Subjects will be exposed to none (N), predictable (P) and unpredictable (U) acoustic and electric shocks.

Secondary Outcome Measures :
  1. Change in emotional expression recognition between SRX246 and Placebo [ Time Frame: up to 7 days ]
    Subjects will be shown pictures of faces exhibiting anger, disgust, fear, happiness, sadness and surprise.

  2. Change in State Anxiety Scale between SRX246 and Placebo [ Time Frame: up to 7 days ]
    Subjects will rate their anxiety level during assessments using a self-administered rating scale.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy male and female volunteers, ages 21-50, inclusive.
  • Subjects able to give their consent and have signed informed consent forms indicating that they understand the purpose and procedures of the study and are willing to participate in the study procedures and restrictions.
  • Body mass index (BMI) of 18.5 to 34.0 kg/m2, inclusive, and a total body weight of >50kg (110 pounds).

Exclusion Criteria:

  • Non-English speakers
  • Current or history of Axis I psychiatric disorder(s) as identified with the Structured Clinical Interview for DSM-IV-TR, non-patient edition (SCID-np) and clinical evaluation.
  • Active or history of active suicidal ideation.
  • Lifetime alcohol or drug dependence according to the Structured Clinical Interview for DSM-IV-TR, non-patient edition (SCID-np).
  • All prescription and non-prescription medications and herbal remedies are prohibited within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication and until at least 7 days or 5 half-lives (whichever is longer) after last dose of study medication, except hormonal contraceptives in females.
  • Clear evidence of a first-degree relative with history of psychosis, bipolar disorder or major depression as determined by the family history method; specifically, participant will know diagnosis or treatment in order to confirm presence of disorder.
  • Subject is currently participating in another clinical trial in which (s)he is or will be exposed to an investigational or non-investigational drug or device, or has done so within the preceding month.
  • Current evidence or history of significant medical illness or organic brain impairment, including syndrome of inappropriate antidiuretic hormone secretion (SIADH), diabetes insipidus (DI), stroke, epilepsy, CNS tumor, demyelinating disease, cardiac, pulmonary, gastrointestinal, renal or hepatic impairment that would likely interfere with the action, absorption, distribution, metabolism, or excretion of SRX246, or influence psychophysiological responses.
  • Current evidence of median nerve entrapment or carpal tunnel syndrome.
  • Any laboratory abnormality that in the investigators' judgment is considered to be clinically significant (ECG, TSH, LFT, etc.).
  • Abnormal urine specific gravity (below 1.00 or above 1.03) as documented by urine sample refractometry.
  • Subject who has resting blood pressure outside of a systolic blood pressure range of 90-140 mmHg or a diastolic blood pressure outside a range of 50-90 mmHg on two consecutive measurements taken up to 10 minutes apart.
  • Subject who has resting pulse rate greater than 100 bpm or less than 50 bpm on two consecutive measurements taken up to 10 minutes apart.
  • Consumption of illicit substances or positive urine toxicology screen throughout the study.
  • Pregnancy, lactating/breastfeeding, or positive pregnancy test.
  • A history of significant drug allergy or systemic allergic disease (e.g., urticaria, atopic dermatitis), or any known/suspected hypersensitivity to SRX246, or allergy to gelatin.
  • Lack of measurable startle response (3 times the baseline EMG activity) for all 9 startles used during the habituation visit.
  • Subjects who would be noncompliant with the visit schedule or study procedures. Possible noncompliance may include planned vacations or planned hospitalizations during the study.
  • For women who are able to get pregnant and men who are able to father a child, unwillingness to use at least two effective birth control methods for 15 days prior to the time they enroll in the study, and for 15 days after their last exposure to the study drug. Effective methods of contraception for this study include:

    1. hormonal contraception (birth control pills, injected hormones or vaginal ring),
    2. intrauterine device,
    3. barrier methods (condom or diaphragm) combined with spermicide, and
    4. surgical sterilization (hysterectomy, tubal ligation, or vasectomy).
  • Employee of NIMH or an immediate family member who is a NIMH employee

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02922166

Layout table for location information
United States, Maryland
National Institute of Mental Health
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
Azevan Pharmaceuticals
National Institute of Mental Health (NIMH)
Layout table for additonal information
Responsible Party: Azevan Pharmaceuticals Identifier: NCT02922166    
Obsolete Identifiers: NCT03036397
Other Study ID Numbers: AVN012
T-M-1970 ( Other Identifier: National Institute of Mental Health )
First Posted: October 4, 2016    Key Record Dates
Last Update Posted: June 10, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Data and samples will be shared with Azevan Pharmaceuticals Inc., its affiliates and research partners working with Azevan Pharmaceuticals Inc.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Anxiety Disorders
Mental Disorders
Antidiuretic Hormone Receptor Antagonists
Molecular Mechanisms of Pharmacological Action
Natriuretic Agents
Physiological Effects of Drugs